EDIT Stock Up 20%: Insider Trading, Hedge Fund Activity and Analyst Ratings
ByAinvest
Monday, Jul 21, 2025 8:04 pm ET1min read
EDIT--
In the past six months, insiders have made a total of 6 trades, with all being sales. This activity indicates a potential bearish sentiment among insiders. However, the stock has seen a net increase in institutional ownership, with 60 investors adding shares and 99 decreasing their positions. This shift suggests a growing interest in the company's prospects.
Analysts have been largely positive about Editas Medicine, with 2 buy ratings and no sell ratings issued in the past month. The median price target stands at $3.5, representing a 13.77% upside from the current price of $2.76. The average price target among analysts is $3.14, with a high forecast of $4.00 and a low forecast of $1.00 [1].
Despite the positive analyst sentiment, Editas Medicine faces significant financial challenges. The company has been operating at a loss, with the previous quarter's earnings per share (EPS) at -$0.92. The next quarter's EPS estimate is -$0.39, with a range of -$0.56 to -$0.29. The company has also been outperforming its industry peers in terms of sales estimates, beating its estimates 50% of the time in the past 12 months [2].
In conclusion, Editas Medicine stock has shown resilience today, with strong institutional buying and positive analyst ratings. However, the company's financial performance remains a concern, with ongoing losses and zero revenue. Investors should closely monitor the company's financials and any new developments in its gene editing technology.
References:
[1] https://www.tipranks.com/stocks/edit/forecast
[2] https://www.tipranks.com/stocks/edit/forecast
$EDIT stock has risen 20% today, with $8.1mln in trading volume. Insiders have made 6 trades in the past 6 months, with 0 purchases and 6 sales. 60 institutional investors have added shares, while 99 have decreased their positions. Analysts have issued 2 buy ratings and 0 sell ratings, with a median price target of $3.5.
Editas Medicine (EDIT) stock has experienced a significant 20% increase today, with trading volume reaching $8.1 million. The stock's performance has been driven by a number of factors, including insider activity, institutional investment, and analyst ratings.In the past six months, insiders have made a total of 6 trades, with all being sales. This activity indicates a potential bearish sentiment among insiders. However, the stock has seen a net increase in institutional ownership, with 60 investors adding shares and 99 decreasing their positions. This shift suggests a growing interest in the company's prospects.
Analysts have been largely positive about Editas Medicine, with 2 buy ratings and no sell ratings issued in the past month. The median price target stands at $3.5, representing a 13.77% upside from the current price of $2.76. The average price target among analysts is $3.14, with a high forecast of $4.00 and a low forecast of $1.00 [1].
Despite the positive analyst sentiment, Editas Medicine faces significant financial challenges. The company has been operating at a loss, with the previous quarter's earnings per share (EPS) at -$0.92. The next quarter's EPS estimate is -$0.39, with a range of -$0.56 to -$0.29. The company has also been outperforming its industry peers in terms of sales estimates, beating its estimates 50% of the time in the past 12 months [2].
In conclusion, Editas Medicine stock has shown resilience today, with strong institutional buying and positive analyst ratings. However, the company's financial performance remains a concern, with ongoing losses and zero revenue. Investors should closely monitor the company's financials and any new developments in its gene editing technology.
References:
[1] https://www.tipranks.com/stocks/edit/forecast
[2] https://www.tipranks.com/stocks/edit/forecast
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet